Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Gross Margin (2022 - 2025)

Historic Gross Margin for Whitehawk Therapeutics (WHWK) over the last 5 years, with Q1 2025 value amounting to 89.36%.

  • Whitehawk Therapeutics' Gross Margin rose 15400.0% to 89.36% in Q1 2025 from the same period last year, while for Sep 2025 it was 89.22%, marking a year-over-year increase of 18300.0%. This contributed to the annual value of 88.36% for FY2024, which is 1000.0% down from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' Gross Margin is 89.36%, which was up 15400.0% from 89.09% recorded in Q4 2024.
  • Whitehawk Therapeutics' 5-year Gross Margin high stood at 100.0% for Q4 2021, and its period low was 85.35% during Q4 2023.
  • Moreover, its 5-year median value for Gross Margin was 89.23% (2024), whereas its average is 90.05%.
  • Per our database at Business Quant, Whitehawk Therapeutics' Gross Margin plummeted by -104100bps in 2023 and then soared by 37400bps in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Gross Margin (Quarter) stood at 100.0% in 2021, then dropped by -4bps to 95.75% in 2022, then fell by -11bps to 85.35% in 2023, then rose by 4bps to 89.09% in 2024, then grew by 0bps to 89.36% in 2025.
  • Its Gross Margin was 89.36% in Q1 2025, compared to 89.09% in Q4 2024 and 88.85% in Q3 2024.